Abstract
Twenty-nine samples of ex vivo ovarian and lung carcinomas were investigated for the relationship between the presence of mutated protein 53 (mp53) and cytotoxic susceptibility. Unaltered expression of MHC class I alleles was required for the cytotoxic susceptibility of tumour cells to the autologous ex vivo blood lymphocytes, i.e. all 4 sensitive tumours belonged to the group of 11 tumours without defect in MHC class I expression. In contrast, the susceptibility did not correlate with the presence of mp53, i.e. cases with mp53 were randomly distributed between the sensitive and resistant tumours (2/4 and 10/17 respectively). There was no correlation either between the p53 mutation and down-regulation of MHC class I alleles. The results suggest that in these tumours the mutated p53 is not the source of immunogenic peptides and that the lack of recognition of the tumours with mp53 is not caused by a defect in the expression of MHC class I molecules.
This is a preview of subscription content, log in via an institution to check access.
References
Bártek J (1991) Genetic and biochemical analysis of mutant p53 in human breast cancer. Oncogene 5:8932
Bártek J, Bártková J, Vojtesek B, Stasková Z, Lukás J, Reithar A, Kovarik J, Midgley CA, Gannon IV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699
Boon T (1992) Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 58:177
Gannon JV (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595
Garrido F, Klein E (eds) (1991) MHC antigen expression. I. Human tumors. Semin Cancer Biol 1: 1
Kaklamanis L, Gatter KC, Hill AB, Mortensen N, Harris AL, Krausa P, McMichael A, Bodmer JG, Bodmer WF (1992) Loss of HLA class I alleles heavy chains and β2-microglobulin in colorectal cancer. Int J Cancer 51:379
Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CHCM, Terada M, Koeffler Ph (1992) p53 mutations in human lung tumors. Cancer Res 52:1695
Neefjes JJ, Breur-Vriesendorp BS, Seventer AG van, Iványi P, Ploegh HL (1986) An improved biochemical method for the analysis of HLA-class I antigens. Definition of new subtypes. Hum Immunol 16:169
Tanaka K, Yoshioka T, Bieberich C, Jay G (1988) Role of major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol 6:359
Vánky F, Klein E, Willems J, Böök K, Ivert T, Péterffy A (1987) Recognition of autologous tumor cells by blood lymphocytes in patients with lung cancer. In: Immunology of malignant disease. MTP, London, p 105
Vánky F, Stuber G, Rotstein S, Klein E (1989) Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC negative tumor cells. Cancer Immunol Immunother 28:17
Végh Zs, Wang P, Vánky F, Klein E (1993) Selectively downregulated expression of MHC class I alleles in human solid tumors. Cancer Res 53:2416
Wang P, Vánky F, Végh Zs, Persson U, Klein E (1991) Expression of MHC class I antigens in human carcinomas and sarcomas analysed by isoelectric focusing. Int J Cancer Suppl 6:106
Wölfel T, Klehmann E, Müller C, Schütt K-H, Mayer zum Büschenfelde K-HMZ, Knuth A (1989) Lysis of human melanoma cells by autologous cytotoxic T cell clones; identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170:797
Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52:4196
Yang SY (1989) Joint reports: In: B. Dupont (ed) HLA-class I polymorphism detected by one-dimensional isoelectric focusing. In: Immunology of HLA, vol 1. Springer, Berlin Heidelberg New York. p 309
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Végh, Z., Wang, P., Vánky, F. et al. Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas. Cancer Immunol Immunother 38, 71–73 (1994). https://doi.org/10.1007/BF01517173
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01517173